Natera shares are trading higher. The company announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

Comments

No comments yet. Be the first!